Yamamura Hisao, Ugawa Shinya, Ueda Takashi, Morita Akimichi, Shimada Shoichi
Dept. of Molecular Morphology, Graduate School of Medical Sciences, Nagoya City Univ., 1 Kawasumi Mizuhocho Mizuhoku, Nagoya 467-8601, Japan.
Am J Physiol Cell Physiol. 2008 Aug;295(2):C296-301. doi: 10.1152/ajpcell.00499.2007. Epub 2008 Jun 4.
The transient receptor potential melastatin subfamily (TRPM), which is a mammalian homologue of cell death-regulated genes in Caenorhabditis elegans and Drosophila, has potential roles in the process of the cell cycle and regulation of Ca(2+) signaling. Among this subfamily, TRPM8 (also known as Trp-p8) is a Ca(2+)-permeable channel that was originally identified as a prostate-specific gene upregulated in tumors. Here we showed that the TRPM8 channel was expressed in human melanoma G-361 cells, and activation of the channel produced sustainable Ca(2+) influx. The application of menthol, an agonist for TRPM8 channel, elevated cytosolic Ca(2+) concentration in a concentration-dependent manner with an EC(50) value of 286 microM in melanoma cells. Menthol-induced responses were significantly abolished by the removal of external Ca(2+). Moreover, inward currents at a holding potential of -60 mV in melanoma cells were markedly potentiated by the addition of 300 microM menthol. The most striking finding was that the viability of melanoma cells was dose-dependently depressed in the presence of menthol. These results reveal that a functional TRPM8 protein is expressed in human melanoma cells to involve the mechanism underlying tumor progression via the Ca(2+) handling pathway, providing us with a novel target of drug development for malignant melanoma.
瞬时受体电位褪黑素亚家族(TRPM)是秀丽隐杆线虫和果蝇中细胞死亡调节基因的哺乳动物同源物,在细胞周期进程和钙(Ca2+)信号调节中具有潜在作用。在该亚家族中,TRPM8(也称为Trp-p8)是一种Ca2+可渗透通道,最初被鉴定为肿瘤中上调的前列腺特异性基因。在此我们表明,TRPM8通道在人黑色素瘤G-361细胞中表达,该通道的激活产生可持续的Ca2+内流。TRPM8通道的激动剂薄荷醇的应用,使黑色素瘤细胞中的胞质Ca2+浓度以浓度依赖的方式升高,其半数有效浓度(EC50)值为286微摩尔。去除细胞外Ca2+可显著消除薄荷醇诱导的反应。此外,在黑色素瘤细胞中,加入300微摩尔薄荷醇可显著增强在-60毫伏的钳制电位下的内向电流。最显著的发现是,在薄荷醇存在下,黑色素瘤细胞的活力呈剂量依赖性降低。这些结果表明,功能性TRPM8蛋白在人黑色素瘤细胞中表达,通过Ca2+处理途径参与肿瘤进展的机制,为我们提供了一个恶性黑色素瘤药物开发的新靶点。